Search - tctmd.com

Displaying 201 - 220 of 410

Sort: Relevancy | Date

FOURIER Surveys Reassure About Cognitive Safety of Evolocumab

News Daily News

FOURIER Surveys Reassure About Cognitive Safety of Evolocumab

May 06, 2020

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

News Daily News

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

Michael O'Riordan

May 04, 2020

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

News Conference News ACC 2020

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

April 02, 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

News Conference News ACC 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Michael O'Riordan

April 02, 2020

Better Adherence to Guideline Advice Pays Off After Acute MI

News Daily News

Better Adherence to Guideline Advice Pays Off After Acute MI

Yael L. Maxwell

March 11, 2020

Optimal LDL levels in patients with ACS undergoing PCI

Presentation JIM 2020

Optimal LDL levels in patients with ACS undergoing PCI

Presenter: Giuseppe Musumeci

February 13, 2020

Ultra LOW LDL is the target for high risk patients

Presentation JIM 2020

Ultra LOW LDL is the target for high risk patients

Presenter: Francesco Prati

February 13, 2020

Optimal LDL Levels In Patients With ACS Undergoing PCI Clinical Case: PCI In ACS Patients With Multivessel Disease

Presentation JIM 2020

Optimal LDL Levels In Patients With ACS Undergoing PCI Clinical Case: PCI In ACS Patients With Multivessel Disease

Presenter: Ferdinando Varbella

February 13, 2020

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2020

January 31, 2020

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

News Daily News

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

Michael O'Riordan

January 14, 2020

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

News Features

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

December 10, 2019

Non-HDL Cholesterol Strongly Tied to Lifetime CVD Risk

News Daily News

Non-HDL Cholesterol Strongly Tied to Lifetime CVD Risk

Michael O'Riordan

December 03, 2019

TCTMD’s Top 10 Most Popular Stories for November 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2019

November 29, 2019

Apabetalone Falls Short in Diabetic ACS Patients With Low HDL: BETonMACE

News Conference News AHA 2019

Apabetalone Falls Short in Diabetic ACS Patients With Low HDL: BETonMACE

Yael L. Maxwell

November 21, 2019

EVAPORATE Hints at Slowed Plaque Progression With Icosapent Ethyl

News Conference News AHA 2019

EVAPORATE Hints at Slowed Plaque Progression With Icosapent Ethyl

November 18, 2019

Lower Cholesterol Cuts CV Events: Treat Stroke to Target Trial

News Conference News AHA 2019

Lower Cholesterol Cuts CV Events: Treat Stroke to Target Trial

November 18, 2019

AHA 2019: Beyond ISCHEMIA Are Plenty of Coronary, Structural, and HF Trials

News Conference News AHA 2019

AHA 2019: Beyond ISCHEMIA Are Plenty of Coronary, Structural, and HF Trials

November 11, 2019

Recurrent Events Common Among Young Patients With CAD

News Daily News

Recurrent Events Common Among Young Patients With CAD

Michael O'Riordan

October 11, 2019

TCTMD’s Top 10 Most Popular Stories for September 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2019

October 01, 2019

Optimizing LDL-C Management in Patients Undergoing Revascularization: More Than Just the Metal

Presentation TCT 2019

Optimizing LDL-C Management in Patients Undergoing Revascularization: More Than Just the Metal

Presenter: Aloke Finn

September 28, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.